In May 2026, the Directorate General of Foreign Trade (DGFT) issued a revised notification tightening controls on the export of non-scheduled Active Pharmaceutical Ingredients (APIs). The circular mandates prior written clearance from the Pharmaceutical Wing, Ministry of Chemicals & Fertilisers, for all API shipments above specified thresholds—a material shift from the previous self-certification route.
Exporters operating under existing IEC codes now face a compressed compliance window ending 30 June 2026, after which shipments lacking approval documentation will face seizure and penalty.
Market signals
DGFT now segments APIs into three risk categories (high-potency, controlled-substance, and common-use) with differentiated approval timelines. High-potency APIs require 45-day pre-approval; others require 15-day notification. This replaces the uniform self-declaration model.
The DGFT has mandated live integration between IEC records and the Ministry of Chemicals' CDSCO-linked API registry. Non-compliance triggers automatic IEC suspension at the ICEGATE portal, freezing all EXIM privileges.
The Ministry has announced spot audits of all API exports made between January–May 2026. Non-compliant shipments face 5–15% customs duty clawback plus 6-month export moratorium per exporter entity.
This notification reshapes IEC-holder obligations under FEMA and DGFT jurisdiction. Pharma exporters must now obtain pre-approval certificates before filing shipping bills—a process requiring fresh documentation (Manufacturing Licence, CDSCO certification, Hazmat clearance). Failure invokes Section 113 of the Customs Act (confiscation) and potential suspension of IEC renewal. Vinayakam Consultants advises immediate audit of your Q1–Q2 shipments and proactive filing of pending approvals to avoid retroactive penalties and reputational damage with customs authorities.
Your action checklist
- Audit all API exports from January 2026 onward against the revised HS code-risk matrix; file amended Pharma Ministry declarations for non-compliant shipments before 20 June 2026.
- Obtain fresh Manufacturing Licence (Form 18B) and CDSCO API Approval Certificate from your state Drugs Controller; cross-verify details against ICEGATE IEC profile to prevent mismatch-triggered suspension.
- Engage a DGFT-credentialed customs broker to prepare and file Category-wise Pre-Export Approval Applications (PEAAs) for all APIs in your product portfolio; allow 6–8 weeks for turnaround.
- Implement a live shipment-tracking protocol linking your ERP to the CDSCO registry; flag any outbound consignment lacking signed approval before airway bill generation to avoid detention and clawback duty.
Frequently asked questions
In May 2026, DGFT issued revised controls requiring prior written approval from the Pharmaceutical Wing for all API exports above specified thresholds. The compliance deadline is 30 June 2026, after which non-compliant shipments face seizure and penalty.
APIs are segmented into three risk tiers: high-potency (45-day pre-approval), controlled-substance, and common-use (15-day notification). Each category has differentiated approval timelines replacing the previous self-certification model.
Non-compliance triggers automatic IEC suspension at the ICEGATE portal, freezing all EXIM privileges. Retroactive audits on Q1 & Q2 shipments may result in 5–15% customs duty clawback and a 6-month export moratorium.